Hodgkin's Lymphoma | Lymphoid Leukemia, Phase I
A Phase Ia/Ib Study of a Novel BTK Inhibitor, DTRMWXHS-12, and Combination Products, DTRM-505 and DTRM-555, in Patients With Chronic Lymphocytic Leukemia or Other B-cell Lymphomas
Volunteers
Health Professionals
What is the purpose of this trial?
This study will evaluate the safety, antitumor activity and preliminary pharmacokinetics of an investigational drug product, DTRMWXHS-12, in patients with chronic lymphocytic leukemia or other B-cell lymphomas. DTRMWXHS-12 will be evaluated as a single agent, and in combination.
This study will be conducted in two parts: phase Ia and Ib. Both parts will explore escalating doses of DTRMWXHS-12. The phase Ia study will evaluate DTRMWXHS-12 monotherapy. The phase Ib study will evaluate DTRMWXHS-12 combinations.
Help Us Discover!
You can help our team find trials you might be eligible for by creating a volunteer profile in MyChart. To get started, create a volunteer profile, or contact helpusdiscover@yale.edu, or call 877.978.8343 for more information.
Principal Investigator
Sub-Investigators
- Agatha Hecht
- Alfredo Axtmayer
- Alison Johnson
- Elan Gorshein, DO, JD, MPH
- Francine Foss, MD
- Iris Isufi, MD
- Jean Vollmer
- Kaitlin Brown
- Karishma Mehra, MBBS
- Kayla Martello
- Madeline Santiago
- Neal Fischbach, MD
- Osarugue Otasowie
- Pawan Karanam, MD
- Shalin Kothari, MD
- Stuart Seropian, MD
- Sudhanshu Mulay, MD
- Syed Ali
- Syed Bilgrami, MBBS
- Tarsheen Sethi, MD, MSc
- Vidya Kesavan
- Last Updated04/16/2024
- Study HIC#2000021088